Evidence map›Paper›PMID 40560501›Full record

GuidelineAnnals of surgical oncology2026

Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors with Peritoneal Involvement.

Elizabeth L Godfrey, Forest Mahoney, Varun V Bansal, David G Su, David N Hanna, Felipe Lopez-Ramirez, Ekaterina Baron, Kiran K Turaga, Al B Benson, Namrata Setia and 13 more

Abstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Elizabeth L GodfreyDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-9258-4706
Forest MahoneyYale School of Medicine, New Haven, CT, USA.
Varun V BansalDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
David G SuDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
David N HannaSection of Surgical Sciences, Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Felipe Lopez-RamirezDepartment of Surgical Oncology, Mercy Medical Center, The Institute for Cancer Care, Baltimore, MD, USA.
Ekaterina BaronDivision of Surgical Oncology, Marshfield Medical Center, Marshfield, WI, USA.
Kiran K TuragaDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA. kiran.turaga@yale.edu.
Al B BensonDivision of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Namrata SetiaDepartment of Pathology, University of Chicago Medical Center, Chicago, IL, USA.
Joshua H WinerDivision of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
Craig G GundersonDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Rupen ShahDivision of Surgical Oncology, Henry Ford Cancer Institute/Henry Ford Health, Detroit, MI, USA.
Deepa R MaggeSection of Surgical Sciences, Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Ian SolskyDivision of Surgical Oncology, Department of Surgery, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Cathy EngDivision of Hematology and Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Oliver S EngDivision of Surgical Oncology, Department of Surgery, University of California Irvine, Orange, CA, USA.
Ardaman ShergillSection of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
John Paul ShenDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joseph MisdrajiDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Michael B FooteDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wenyi LuoDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Peritoneal Surface Malignancies (PSM) Consortium Group

Funding

Surgical Oncology Training GrantT32CA106183 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI James Richard Goldenring · 2004 to 2026
$6.0M
Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)T32CA233414 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 2019 to 2026
$3.2M
CPRIT Scholar in Cancer Research RR180035NCI NIH HHS T32 CA106183NCI NIH HHS T32 CA233414
6 · The paper itself

Abstract

backgroundAppendiceal tumors comprise a heterogeneous group of tumors that frequently disseminate to the peritoneum. Management of appendiceal tumors is lacking high quality data given their rarity and heterogeneity. In general, appendiceal tumor treatment is extrapolated in part from colorectal cancer or pooled studies, without definitive evidence of disease-specific benefit. Many practices are controversial and vary widely between institutions. A national consensus update of best management practices for appendiceal malignancies was performed to better standardize care. Herein the authors present recommendations for the management of appendiceal tumors with peritoneal involvement.

methodsAs previously described, modified Delphi consensus was performed to update the previous 2018 Chicago consensus guideline. Recommendations were supported by using rapid systematic reviews of key issues in surgical and systemic therapy. Key pathology concepts and recommendations were synthesized in collaboration with content experts.

resultsA consensus-based pathway was generated for any type of non-neuroendocrine appendiceal tumor with peritoneal involvement. The first round of Delphi consensus included 138 participants, of whom 133 (96%) participated in the second round, and greater than 90% consensus was achieved for all pathway blocks. Key items include recommending evaluation for cytoreduction to most patients with low-grade peritoneal disease who are surgical candidates, and to many patients with high-grade disease, as well as timing of systemic chemotherapy and surveillance protocols. Common pitfalls in pathologic classification and their clinical implications are also presented.

conclusionThese consensus recommendations provide guidance regarding the management of appendiceal tumors with peritoneal involvement, including a review of current evidence in the management of recurrent and unresectable disease.

Indexed as

Appendiceal NeoplasmsPeritoneal NeoplasmsPractice Guidelines as TopicConsensusCytoreduction Surgical ProceduresDelphi TechniqueHumansPrognosisAppendiceal malignanciesCytoreductive surgical proceduresGuidelinesPeritoneal neoplasmsPeritoneal surface malignancies

Identifiers

PMID40560501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.